You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Adding Epoetin Alfa to Intense Dose-Dense Adjuvant Chemotherapy for Breast Cancer: Randomized Clinical Trial
|
|---|---|
| Published in |
JNCI: Journal of the National Cancer Institute, July 2013
|
| DOI | 10.1093/jnci/djt145 |
| Pubmed ID | |
| Authors |
Volker Moebus, Christian Jackisch, Andreas Schneeweiss, Jens Huober, Hans-Joachim Lueck, Andreas du Bois, Christoph Thomssen, Christian Kurbacher, Walther Kuhn, Ulrike Nitz, Ingo B. Runnebaum, Axel Hinke, Rolf Kreienberg, Michael Untch |
| Abstract |
The AGO-ETC trial compared 5-year relapse-free survival of intense dose-dense (IDD) sequential chemotherapy with epirubicin (E), paclitaxel (T), and cyclophosphamide (C) (IDD-ETC) every 2 weeks vs conventional scheduled epirubicin/cyclophosphamide followed by paclitaxel (EC→T) (every 3 weeks) as adjuvant treatment in high-risk breast cancer patients. The objective of this study was to evaluate the safety and efficacy of epoetin alfa in a second randomization of the intense dose-dense arm. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 50% |
| Belgium | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 78 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| United States | 1 | 1% |
| Ecuador | 1 | 1% |
| Unknown | 75 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Other | 11 | 14% |
| Researcher | 10 | 13% |
| Student > Bachelor | 10 | 13% |
| Student > Master | 6 | 8% |
| Lecturer | 3 | 4% |
| Other | 14 | 18% |
| Unknown | 24 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 31 | 40% |
| Nursing and Health Professions | 8 | 10% |
| Biochemistry, Genetics and Molecular Biology | 3 | 4% |
| Agricultural and Biological Sciences | 3 | 4% |
| Psychology | 2 | 3% |
| Other | 5 | 6% |
| Unknown | 26 | 33% |
Attention Score in Context
This research output has an Altmetric Attention Score of 36. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 July 2022.
All research outputs
#1,127,740
of 25,394,764 outputs
Outputs from JNCI: Journal of the National Cancer Institute
#725
of 7,848 outputs
Outputs of similar age
#9,223
of 206,434 outputs
Outputs of similar age from JNCI: Journal of the National Cancer Institute
#12
of 106 outputs
Altmetric has tracked 25,394,764 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 7,848 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 21.2. This one has done particularly well, scoring higher than 90% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 206,434 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 106 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 88% of its contemporaries.